L. Beyer

TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis

S. Klebe, R. Gold, K. Gerwert, 2020, Annals of clinical and translational neurology.

Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years

D. Rujescu, K. Gerwert, B. Holleczek, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

JOINT CONTRIBUTION OF MARKERS OF NEURODEGENERATION AND HYPERCHOLESTEROLEMIA TO DEMENTIA RISK

R. Perneczky, K. Gerwert, U. Mons, 2022, medRxiv.

Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies

Sebastian Schuster, A. Danek, S. Stoecklein, 2022, medRxiv.

High cholesterol levels change the association of biomarkers of neurodegenerative diseases with dementia risk: Findings from a population‐based cohort

B. Schöttker, R. Perneczky, K. Gerwert, 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers

D. Rujescu, B. Schöttker, K. Gerwert, 2023, JAMA network open.

Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

D. Rujescu, B. Schöttker, K. Beyreuther, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Update on CSF Biomarkers in Parkinson’s Disease

R. Gold, K. Gerwert, L. Tönges, 2022, Biomolecules.

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure.

K. Gerwert, J. Gumbart, V. Batista, 2020, Biophysical journal.

Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study

L. Perna, C. Kurz, L. Beyer, 2023, Alzheimer's Research & Therapy.